Gsk (GSK) Minority Interest (2009 - 2026)

Gsk (GSK) has 18 years of Minority Interest data on file, last reported at -$627.9 million in Q2 2026.

• For the quarter ending Q2 2026, Minority Interest fell 7.71% year-over-year to -$627.9 million; the trailing twelve-month figure through Jun 2026 stood at -$627.9 million (down 7.71% YoY), and the FY2025 full-year result was -$560.0 million, up 25.11% from the prior year.
• Minority Interest was -$627.9 million for Q2 2026 at Gsk, down from -$579.7 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $8.7 billion in Q1 2022 to a low of -$775.1 million in Q1 2024.
• A 5-year average of $350.0 million and a median of -$622.7 million in 2023 frame the typical range for Minority Interest.
• Across the five-year window, Minority Interest sank 108.44% in 2023 and grew 25.9% in 2025, its largest moves.
• Gsk's Minority Interest stood at -$588.8 million in 2022, then decreased by 16.36% to -$685.1 million in 2023, then declined by 9.59% to -$750.8 million in 2024, then increased by 25.42% to -$560.0 million in 2025, then declined by 12.13% to -$627.9 million in 2026.
• Per Business Quant data, the three most recent Minority Interest figures were -$627.9 million in Q2 2026, -$579.7 million in Q1 2026, and -$560.0 million in Q4 2025.